B0935
盐酸贝那普利 盐酸盐
≥98% (HPLC), solid
别名:
(3S)-3-[[(1S)-1-(乙氧羰基)-3-苯丙基]氨基]-2,3,4,5-四氢-2-氧代-1H-1-苯并氮杂卓-1-乙酸 盐酸盐
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C24H28N2O5 · HCl
化学文摘社编号:
分子量:
460.95
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
solid
solubility
H2O: >5 mg/mL
originator
Novartis
SMILES string
Cl[H].CCOC(=O)[C@H](CCc1ccccc1)N[C@H]2CCc3ccccc3N(CC(O)=O)C2=O
InChI
1S/C24H28N2O5.ClH/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28;/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28);1H/t19-,20-;/m0./s1
InChI key
VPSRQEHTHIMDQM-FKLPMGAJSA-N
Gene Information
human ... ACE(1636)
Biochem/physiol Actions
贝那普利是一种长效的血管紧张素转换酶 (ACE) 抑制剂。
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under 盐酸贝那普利 盐酸盐
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Yoshihiko Kanno et al.
Hypertension research : official journal of the Japanese Society of Hypertension, 25(6), 939-943 (2002-12-18)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disorder in humans. Hypertension is one of the major complications, and its control might affect the renal survival and disease mortality. Suitable antihypertensive agents have been discussed based
Daphne P Bicket
American family physician, 66(3), 461-468 (2002-08-17)
When first introduced in 1981, angiotensin-converting enzyme (ACE) inhibitors were indicated only for treatment of refractory hypertension. Since then, they have been shown to reduce morbidity or mortality in congestive heart failure, myocardial infarction, diabetes mellitus, chronic renal insufficiency, and
Nadine Bongaerts et al.
Nature communications, 13(1), 3905-3905 (2022-07-08)
Whole-cell screening for Mycobacterium tuberculosis (Mtb) inhibitors is complicated by the pathogen's slow growth and biocontainment requirements. Here we present a synthetic biology framework for assaying Mtb drug targets in engineered E. coli. We construct Target Essential Surrogate E. coli
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| B0935-250MG | 04061832895727 |
| B0935-500MG | 04061832895734 |